Health
ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., May 07, 2025--ENHERTU Followed by THP Showed Statistically Significant Improvement in pCR in HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Trial
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/81423b1a7eff070ca1ff67ab3e82f205"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U6mVshoT4DuKUthEGTvZMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/81423b1a7eff070ca1ff67ab3e82f205","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Daiichi Sankyo and AstraZeneca’s ENHERTU followed by THP showed an improved safety profile versus standard of care","length":114,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer","length":76,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Results will be shared with regulatory authorities","length":50,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":240,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., May 07, 2025--(BUSINESS WIRE)--Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2 positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment.","length":731,"tagName":"p"},{"type":"text","content":"The secondary endpoint of event-free survival (EFS) was not mature at the time of this analysis; however, EFS data showed an early positive trend favoring ENHERTU followed by THP compared to standard of care. The trial will continue to follow EFS.","length":247,"tagName":"p"},{"type":"text","content":"ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LS...